In December 2012, Empower Magazine featured an “Empowering First” spotlight on Darnisha Grant Harrison, one of the first African American females to serve as founder, president and CEO of a pharmaceutical company in the U.S.
In observance of Black History Month, we salute Ennaid Therapeutics enterprising founder and catch up on the company’s latest cutting-edge research and developments.
The bio-pharmaceutical company will be featured on an upcoming episode of the award-winning television series, Innovations with Ed Begley Jr., airing in the 1st quarter of 2016 on the Discovery Channel. (Dates and show times TBA) The episode will highlight Ennaid Therapeutics ongoing quest to develop proprietary therapeutic cures (not vaccines) for the 400-plus million people worldwide who contract Zika Virus and Dengue Virus, the world’s fastest growing pandemic.
(February 5, 2016) – Ennaid Therapeutics, a bio-pharmaceutical company based in Alpharetta, Ga., is developing therapeutic cures (not vaccines) to help the millions of people worldwide when they are actually infected with the mosquito-borne disease, Zika Virus, now named a global public health emergency by the World Health Organization (WHO).
This is the fourth time that the WHO has issued a global emergency classification. Previously, the Ebola outbreak in 2014, a resurgence of polio in 2014 and the H1N1 pandemic in 2009, received such classifications. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil and now almost a million cases have been recorded in more than 30 countries in multiple world regions – along with a variety of rumored transmission methods.
The global health community is urging caution and care in contracting the virus, and is calling for rapidly stepped up efforts by researchers to find therapies for those who contract it. Ennaid Therapeutics has been committed to finding care solutions to all mosquito borne diseases, including Dengue fever, Chikungunya and Zika virus – and is now advancing its work on Zika to address the urgent global need.
“At its recent meeting in Davos, the World Economic Forum designated infectious disease as a key global challenge and neglected tropical diseases, such as Zika virus, is one of those we must be vigilant and dedicated to finding therapies for as more people quickly become infected,” says Darnisha Harrison, Ennaid Therapeutics’ CEO.
- Over one million people die from mosquito-borne diseases every year, and hundreds of millions more experience pain and suffering from illnesses transmitted by mosquitoes.
- The most common symptoms of Zika virus disease are fever, rash, joint pain, and conjunctivitis (red eyes). Other common symptoms include muscle pain and headache.
- Zika is spread by the same mosquito family, Aedes aegypti that carries Dengue fever, Chikungunya and Yellow Fever.
- The incubation period (the time from exposure to symptoms) for Zika virus disease is not known, but is likely to be a few days to a week.
- Zika virus usually remains in the blood of an infected person for about a week but it can be found longer in some people.
- Currently there is no vaccine to prevent or specific medicine to treat Zika infections. In the United States there are currently 48 patients in 12 states infected and for the first time, a health emergency has been declared in the nation because of the Zika virus. An estimated 4 million infections are expected to be diagnosed in the Americas in 2016 according to predictions.
Adds CEO Harrison, “To this, our work must also continue to find treatments for the growing numbers of Dengue, West Nile and Chikungunya sufferers, among other mosquito spread viruses.”
Click the link below for information on the upcoming Discovery channel production of “Innovations with Ed Begley, Jr.” in which Ennaid Therapeutics will be featured describing their work on neglected disease therapies including the Zika Virus and Dengue Virus:
About Ennaid Therapeutics science:
► Our scientific methodology are very strong and established.
► Our peptides show significant inhibition against many Flaviviridae family of viruses, such as Dengue and possibly Zika, which are both carried by the same Aedes species mosquito, both of the flavivirus genus.
► The stem of our peptides mimics the stem of many Flaviviridae viruses, thus inhibiting viral infection. ► Zika stem is a very close match to our peptide’s stem and we are currently doing feasibility and development studies to determine our peptide’s inhibitory action against Zika virus and its safety both in vivo and in pregnancy.
► There is known evidence that already commercialized peptide fusion inhibitors are indeed safe, such as, Enfuvirtide (brand name Fuzeon). Once safety is demonstrated, a fast-track development strategy would allow Ennaid Therapeutics to begin clinical trials immediately as funding is secured.
► Our team of scientists and business professionals are veterans with long, direct experience in the infectious diseases field; and Ennaid Therapeutics is well positioned to address the explosive Zika virus crisis (as well as other vector borne disease efforts) in the immediate term.
Background on Ennaid Therapeutics
The company strongly believes that there is good, impactful science not being explored by big mass-pharma beyond early laboratory tests. We have chosen to specialize our efforts and target our focus on diseases which affect billions – and often the most ignored – and to fill a gap which larger bio-companies purposefully do not.
Our successful strategy is in acquiring early-stage, proprietary, innovative science to create industry-accepted, fast-track development treatments to bring 1st-to-market, profitable cures to the global mass market that disrupt rare and seemingly incurable diseases.
Acquiring the best, most promising early-stage science to bring medicines to market that cure diseases, versus just managing managing them or neglecting is our passionate calling.
The first such promising scientific technology that Ennaid Therapeutics acquired was from Florida Gulf Coast University in Fort Myers, FL and the University of Washington in Seattle, WA. It is a proprietary technology that shows 99% effectiveness against all four strains of Dengue fever virus and West Nile virus infectivity. Our fast-track development plan will safely and rapidly get these cures to market in record time with project completion anticipated by December, 2016. Therefore, a therapeutic cure could be on the market by December, 2018.
About Darnisha Grant Harrison, Ennaid’s founding CEO
Darnisha Grant Harrison is one of the first African American women in the world to be the founder, president & CEO of a bio-pharmaceutical company. In this role she’s responsible for guiding the strategic direction and growth of Ennaid Therapeutics. Once a microbiologist and chemist, Harrison is a nationally recognized science entrepreneur with 22-plus years of experience in the Life Sciences. Prior to founding Ennaid Therapeutics in 2012, she spent 3 years as a scientist at Amgen and the University of Georgia, and 16-years in Business Development/Licensing as a Director for various pharmaceutical’s companies; notably Penwest/JRS Pharma; Metrics, Inc; Banner Pharmacaps and Norwich Pharmaceuticals. An expert negotiator and deal-maker she has identified, negotiated and closed drug development deals and strategic collaborations her entire career, and is expertly skilled in technology acquisition, licensing, strategic business development, business planning and brisk, successful execution of such plans. A member of the American Association for the Advancement of Science and the New York Academy of Sciences, she received her bachelor of science in microbiology and minor in chemistry from LSU.
For more information visit Ennaid Therapeutics at Web: http://ennaidtherapeutics.com/ Facebook: https://www.facebook.com/ennaidtherapeutics/ Twitter: @ennaidcures LinkedIn: ennaid-therapeutics